G. Belcher
Research Subjects
G. Belcher has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
C. Lambert
Takeda Europe R & D Centre, London, UK
1 shared publicationG. Edwards
Takeda Europe R & D Centre, London, UK
1 shared publicationG. Schernthaner
Takeda Europe R&D Centre, London, UK
1 shared publication- Kah Lay Goh
Takeda Europe R & D Centre, London, UK
1 shared publication M. Valbuena
Takeda Europe R & D Centre, London, UK
1 shared publication
Latest Publications
- 13 July 2005
- Published by Wiley in Diabetic Medicine
- Vol. 22 (8) , 973-979
Changes in liver tests during 1‐year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide
Aims Patients with Type 2 diabetes are at increased risk of liver damage. Therefore, it is of particular importance to investigate the hepatic effects of drugs used to treat such patients.Methods Liver testing results performed in four 1‐year, randomized, double‐blind studies comparing effects of pioglitazone, metformin or a sulphonylurea, gliclazide, in the treatment of over 3700 patients with Type 2 diabetes have been analysed.Results Pioglitazone caused reductions in mean levels of hepatic enzymes of between 3 and 18%, whilst gliclazide caused small increases of between 3 and 13%. Metformin treatment showed either small mean increases or decreases. More patients receiving pioglitazone had liver tests within the normal range at the end of treatment (≥ 87%) compared with patients receiving metformin (≥ 80%) or gliclazide (≥ 75%). Slightly fewer patients with pioglitazone than with comparators showed a large increase (> 3 upper limit of normal) in alanine aminotransferase levels at any time during treatment (pioglitazone 0.9%, metformin 1.9%, gliclazide 1.9%).Conclusions During pioglitazone treatment there is a reduction in liver enzyme levels. Although the mechanism of this effect is not clear, the results demonstrate potential beneficial effects on the liver during treatment of patients with Type 2 diabetes with pioglitazone.
- 13 July 2005
- Published by Wiley in Diabetic Medicine
- Vol. 22 (8) , 973-979
Changes in liver tests during 1‐year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide
Aims Patients with Type 2 diabetes are at increased risk of liver damage. Therefore, it is of particular importance to investigate the hepatic effects of drugs used to treat such patients.Methods Liver testing results performed in four 1‐year, randomized, double‐blind studies comparing effects of pioglitazone, metformin or a sulphonylurea, gliclazide, in the treatment of over 3700 patients with Type 2 diabetes have been analysed.Results Pioglitazone caused reductions in mean levels of hepatic enzymes of between 3 and 18%, whilst gliclazide caused small increases of between 3 and 13%. Metformin treatment showed either small mean increases or decreases. More patients receiving pioglitazone had liver tests within the normal range at the end of treatment (≥ 87%) compared with patients receiving metformin (≥ 80%) or gliclazide (≥ 75%). Slightly fewer patients with pioglitazone than with comparators showed a large increase (> 3 upper limit of normal) in alanine aminotransferase levels at any time during treatment (pioglitazone 0.9%, metformin 1.9%, gliclazide 1.9%).Conclusions During pioglitazone treatment there is a reduction in liver enzyme levels. Although the mechanism of this effect is not clear, the results demonstrate potential beneficial effects on the liver during treatment of patients with Type 2 diabetes with pioglitazone.
- 20 October 2004
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (9) , 833-837
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide
Cardiovascular mortality and morbidity are increased in patients with type 2 diabetes. However, there are few data from clinical trials comparing cardiovascular effects of alternative oral anti‐diabetic agents. Major cardiovascular outcomes during four one‐year, double‐blind trials in over 3700 patients with type 2 diabetes randomised to either a thiazolidinedione, pioglitazone, metformin or a sulphonylurea, gliclazide treatment have been combined. Mean blood pressure was slightly reduced by all treatments, with pioglitazone treatment resulting in the largest falls (approximately 1.5 mmHg). Hospitalisations for cardiac or cerebrovascular events were similar with the different treatments. Overall mortality was seven of 1857 for pioglitazone and 10 of 1856 for non‐pioglitazone treatments, of which three and six were cardiac deaths, respectively. The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non‐pioglitazone (10/1856) treatments. The results show similar cardiovascular outcome for the three different treatments over a one‐year period, but demonstrate interesting differences, which will require longer‐term formal outcome studies to determine their significance.
- 20 October 2004
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (9) , 833-837
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide
Cardiovascular mortality and morbidity are increased in patients with type 2 diabetes. However, there are few data from clinical trials comparing cardiovascular effects of alternative oral anti‐diabetic agents. Major cardiovascular outcomes during four one‐year, double‐blind trials in over 3700 patients with type 2 diabetes randomised to either a thiazolidinedione, pioglitazone, metformin or a sulphonylurea, gliclazide treatment have been combined. Mean blood pressure was slightly reduced by all treatments, with pioglitazone treatment resulting in the largest falls (approximately 1.5 mmHg). Hospitalisations for cardiac or cerebrovascular events were similar with the different treatments. Overall mortality was seven of 1857 for pioglitazone and 10 of 1856 for non‐pioglitazone treatments, of which three and six were cardiac deaths, respectively. The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non‐pioglitazone (10/1856) treatments. The results show similar cardiovascular outcome for the three different treatments over a one‐year period, but demonstrate interesting differences, which will require longer‐term formal outcome studies to determine their significance.